Russell Investments determines membership for its equity indexes
primarily by objective, market-capitalization rankings and style
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, recently initiated a phase
2/3 study for the treatment of childhood cerebral adrenoleukodystrophy
(CCALD), a rare, hereditary neurological disorder affecting young boys.
The next most advanced product candidate, LentiGlobin, is currently in a
phase 1/2 study in
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of our clinical trials. Any
forward-looking statements in this press release are based on
management's current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties
include, but are not limited to, the risk of cessation or delay of any
of the ongoing or planned clinical trials and/or our development of our
product candidates, the risk that the results of previously conducted
studies involving similar product candidates will not be repeated or
observed in ongoing or future studies involving current product
candidates, the risk that our collaboration with
Source: bluebird bio, Inc.
bluebird bio, Inc
Richard E. T. Smith, Ph.D., 617-588-3321
Pure Communications, Inc.
Dan Budwick, 973-271-6085